Healthcare Business - Page 2

Breakthrough Gastrointestinal Tumor Therapy Reaches New Milestone

Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) shares nearly doubled on Tuesday after the firm announced top-line results from its late-stage trial treating patients with gastrointestinal stromal tumors (GIST). Specifically, this data ...
Read Full Story »

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

Over the past three decades, the unlimited investing potential of biotechnology was all about growth. Companies could grow from nothing to see untold billions of dollars selling cures and treatments ...
Read Full Story »

8 Biotechs Being Choked by Short Sellers

This has been a hard year for biotech. It seems that both Democrats and Republicans are wanting to target drug prices, and fears of universal health care in the years ...
Read Full Story »

Short Sellers Make a Move on Big Biotechs

The short interest data are out for the most recent settlement date, July 31. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Major Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Is Amarin’s Cardio Trial in Trouble?

Amarin Corp. PLC (NASDAQ: AMRN) shares dropped on Friday after the firm announced that it received notice from the U.S. Food and Drug Administration (FDA). According to the notice, the ...
Read Full Story »

Revolutionary Peanut Allergy Treatment Is One Step Closer

Shares of DBV Technologies S.A. (NASDAQ: DBVT) shot up on Thursday after the company announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration ...
Read Full Story »

What These Late-Stage Obesity Studies Could Mean for the Future of Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) shares jumped on Wednesday after the company announced positive results from two of its late-stage obesity clinical trials. Specifically, the data come from two Phase ...
Read Full Story »

Insulin Delivery Growth Driving Insulet Higher and Higher

Aren't politicians going after drug prices and just about any costs tied to health care that they can get their hands and minds around? That may be the case during ...
Read Full Story »

Good News for Insomnia, Major Depression and Schizophrenia

Minerva Neurosciences, Inc. (NASDAQ: NERV) shares jumped on Monday after the company announced positive topline results from its two mid-stage studies in major depressive disorder (MDD) and insomnia. Specifically, these ...
Read Full Story »

Is GlycoMimetics’ Sickle Cell Study Done For?

GlycoMimetics Inc. (NASDAQ: GLYC) shares were crushed on Monday after the firm announced late-stage results from its sickle cell disease (SCD) trial in conjunction with Pfizer Inc. (NYSE: PFE). SCD ...
Read Full Story »

Study: Vitamin A May Lower Skin Cancer Risk

Vitamin D is known as “the sunshine vitamin” because sunlight spurs its creation in the body. A new study suggests that one of its counterparts, vitamin A, might be the ...
Read Full Story »

Why Amgen Is Up Despite Falling Product Sales

When Amgen Inc. (NASDAQ: AMGN) released its second-quarter financial results after the markets closed on Tuesday, the firm said that it had $3.97 in earnings per share (EPS) and $5.9 ...
Read Full Story »

Why Keytruda Made All the Difference in Merck’s Q2

Merck & Co. Inc. (NYSE: MRK) released its second-quarter financial results before the markets opened on Tuesday. The pharma giant said that it had $1.30 in earnings per share (EPS) ...
Read Full Story »

What to Watch When Merck and Pfizer Report Early on Tuesday

Pfizer Inc. (NYSE: PFE) and Merck & Co. Inc. (NYSE: MRK) are each scheduled to release their second-quarter financial results before the markets open on Tuesday. These are just a ...
Read Full Story »